Key study findings include:

• More patients were able to tolerate and remain on the maximum daily dose of ARICEPT (10 mg once daily) than the maximum daily dose of Reminyl (12 mg twice daily) (92 percent vs. 71 percent) until study end or final patient visit. Almost one-quarter of Reminyl-treated patients titrated down from the maximum dose to a lower maintenance dose due to tolerability.
• Significantly greater improvements in cognition were observed for ARICEPT compared with Reminyl. At Week 12 and endpoint (Week 12 LOCF), ARICEPT-treated patients showed at least a two-point advantage over patients receiving Reminyl on the 13-item modified ADAS-cog scale (p-value < 0.05). Modified ADAS-cog assesses elements of cognition including the ability to recognize and recall words, comprehend spoken language, and name fingers and objects. The modified version used in this trial added two additional items: delayed recall and concentration/distractibility.
• At endpoint, ARICEPT-treated patients achieved significant improvements over patients receiving Reminyl, as measured using the MMSE (p-value < 0.05).
• Patients receiving ARICEPT had significantly greater improvements in ADLs than those receiving Reminyl, according to the DAD total score (p-value <0.05 at both Week 12 and endpoint). DAD assesses instrumental and basic ADLs such as preparing meals, handling finances and correspondence and eating.
• More gastrointestinal adverse events were observed in Reminyl-treated patients than the ARICEPT treatment group. More patients taking Reminyl reported nausea and diarrhea than those taking ARICEPT(23.2 percent vs. 15.6 percent and 14.3 percent vs. 9.4 percent, respectively). Almost 13 percent of patient
  '"/>